Chitotriosidase as a novel biomarker of early atherosclerosis in hemodialysis patients
HEMODIALYSIS INTERNATIONAL, vol.21, no.1, pp.41-46, 2017 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 21 Issue: 1
- Publication Date: 2017
- Doi Number: 10.1111/hdi.12451
- Journal Name: HEMODIALYSIS INTERNATIONAL
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.41-46
- Keywords: Chitotriosidase (CHIT-1), atherosclerosis, intima media thickness, hemodialysis, CORONARY-ARTERY-DISEASE, INTIMA-MEDIA THICKNESS, PLASMA CHITOTRIOSIDASE, CARDIOVASCULAR RISK, KIDNEY-DISEASE, MARKERS, PLAQUE, MACROPHAGES, MECHANISMS, CHITINASE
- Open Archive Collection: AVESIS Open Access Collection
- Kütahya Health Sciences University Affiliated: No
Abstract
Introduction: Increasing evidence suggests that inflammation and increased macrophage activity have a central role in pathogenesis of atherosclerosis. It is shown that chitotriosidase (CHIT-1) is a marker of macrophage activity in atherosclerotic plaque, and is found associated with severity of atherosclerotic lesion. There is no data about CHIT-1 activity of hemodialysis patients in the literature. Thus, we hypothesized that in hemodialysis patients, CHIT-1 levels might be a novel biomarker in early atherosclerosis. Methods: Forty-five hemodialysis patients were included in the study (age: 61.93 +/- 613.34). Intima media thickness (IMT) was evaluated with high-resolution B-mode ultrasonography. Biomarker levels were measured in serum of patients. Findings: We found positive correlation among IMT, age (R: 0.426, P: 0.004) and, CHIT-1 value (R: 0.462, P: 0.001) in spearman correlation analysis. When age, CRP, creatinine, P, Alb, CHIT-1 were chosen as measures that can effect IMT in multiple regression model, IMT level was related with CHIT-1 (Beta: 0,396, P: 0.012) and age (Beta: 0,313 P: 0,048) independently. Discussion: In conclusion, this is the first report showing that serum CHIT-1 level was related independently with carotid IMT in hemodialysis patients. This biomarker might have an unknown role in the development of atherosclerosis during uremia.